{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:05:12Z","timestamp":1776312312333,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) or R\/R mantle cell lymphoma (MCL). An unanchored matching-adjusted indirect comparison (MAIC) was performed in R\/R CLL\/SLL patients. Individual patient data from zanubrutinib trial (BGB-3111-205) were adjusted to match the aggregated data from the orelabrutinib trial (ICP-CL-00103). A na\u00efve comparison was performed in R\/R MCL for the different response assessment methodology and efficacy analysis set between the zanubrutinib (BGB-3111-206) and orelabrutinib (ICP-CL-00102) trials. Efficacy outcomes included ORR and PFS. In R\/R CLL\/SLL patients, after matching, IRC-assessed ORR was comparable (86.6% vs. 92.5%; risk difference, -5.9% [95% CI: -15.8%-3.8%]); IRC-assessed PFS was similar with a favorable trend in zanubrutinib over orelabrutinib (HR, 0.74 [95% CI: 0.37-1.47]) and the 18-month PFS rate was numerically higher in zanubrutinib (82.9% vs. 78.7%). In R\/R MCL patients, na\u00efve comparison showed investigator-assessed ORR was similar (83.7% vs. 87.9%; risk difference, -4.2% [95% CI: -14.8%-6.0%]), and CR rate was significantly higher in zanubrutinib over orelabrutinib (77.9% vs. 42.9%; risk difference, 35.0% [95% CI: 14.5%, 53.7%]). Investigator-assessed PFS was similar with a favorable trend (HR, 0.77 [95% CI: 0.45-1.32]) in zanubrutinib over orelabrutinib and the 12-month PFS rate was numerically higher in zanubrutinib (77.5% vs. 70.8%). MAIC result showed zanubrutinib demonstrated favorable PFS over orelabrutinib for R\/R CLL\/SLL patients. The na\u00efve comparison showed zanubrutinib had favorable PFS and higher CR rate than orelabrutinib for R\/R MCL patients.<\/jats:p>","DOI":"10.1007\/s10637-023-01376-1","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T02:01:56Z","timestamp":1688781716000},"page":"606-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Yuqin","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenmiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/ijc.29326","volume":"136","author":"S Bernard","year":"2015","unstructured":"Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F (2015) Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer 136:2761\u20132774. https:\/\/doi.org\/10.1002\/ijc.29326","journal-title":"Int J Cancer"},{"key":"1376_CR2","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood J Am Soc Hematol 118:4313\u20134320. https:\/\/doi.org\/10.1182\/blood-2011-06-338855","journal-title":"Blood The Journal of the American Society of Hematology"},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Wiestner A (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 23:410\u2013421. https:\/\/doi.org\/10.1016\/j.semcancer.2013.09.001","journal-title":"Semin Cancer Biol"},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nri955","volume":"2","author":"H Niiro","year":"2002","unstructured":"Niiro H, Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2:945\u2013956. https:\/\/doi.org\/10.1038\/nri955","journal-title":"Nat Rev Immunol"},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"1799 \u20131807","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. 3:1799\u20131807. https:\/\/doi.org\/10.1182\/bloodadvances.2018028761","journal-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies."},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075\u201313080. https:\/\/doi.org\/10.1073\/pnas.1004594107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW (2019) Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134:851\u2013859. https:\/\/doi.org\/10.1182\/blood.2019001160","journal-title":"Blood"},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fern\u00e1ndez de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M (2020) A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood 136:2038\u20132050. https:\/\/doi.org\/10.1182\/blood.2020006844","journal-title":"Blood"},{"key":"1376_CR9","doi-asserted-by":"crossref","unstructured":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, \u0160imkovi\u010d M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, \u00d6sterborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W (2022) Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a Randomized Phase III Trial. J Clin Oncol JCO 22.00510","DOI":"10.1200\/JCO.22.00510"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M (2023) Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 388:319\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1158\/1538-7445.AM2020-CT132","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhao R, Liang R, Gao Y, Liu R, Chen X, Wang Z, Yu L, Shakib Z, Cui J (2020) Orelabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties. Cancer Res 80:132","journal-title":"Cancer Res"},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A (2017) Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 363:240\u2013252. https:\/\/doi.org\/10.1124\/jpet.117.242909","journal-title":"J Pharmacol Exp Ther"},{"key":"1376_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam CS, Ou YC, Trotman J, Opat S (2021) Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol 14:1329\u20131344. https:\/\/doi.org\/10.1080\/17512433.2021.1978288","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2021-148544","volume":"138","author":"M Shadman","year":"2021","unstructured":"Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Cultrera JL, Misleh J, Zafar SF, Freeman B, Rao SS, Yimer H, Chaudhry A, Gandhi MD, Guthrie TH, Kingsley E, Tumula PK, Manda S, Chen D-Y, Cohen A, By K, Xu L, Liu Y, Sharman JP (2021) Phase 2 study of Zanubrutinib in BTK inhibitor-intolerant patients (pts) with Relapsed\/Refractory B-Cell malignancies. Blood 138:1410\u20131410. https:\/\/doi.org\/10.1182\/blood-2021-148544","journal-title":"Blood"},{"key":"1376_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM (2010) Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics 28:935\u2013945. https:\/\/doi.org\/10.2165\/11538370-000000000-00000","journal-title":"PharmacoEconomics"},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J (2020) Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol 13:48. https:\/\/doi.org\/10.1186\/s13045-020-00884-4","journal-title":"J Hematol Oncol"},{"key":"1376_CR17","unstructured":"Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J (2021) Feng R Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results. In: European Hematology Association 2021 Virtual Congress"},{"key":"1376_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.43_2880","author":"W Xu","year":"2021","unstructured":"Xu W, Song Y, Wang T, Yang S, Liu L, Hu Y, Zhang W, Zhou J, Gao S, Ding K, Zhang H, Zhu Z, Wang S, Xu B, Hu J, Liu T, Ji C, Xia Z, Li Y, Wang X, Zhao R, Zhang B, Li J (2021) Updated efficacy and safety results of orelabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia\/small cell leukemia. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.43_2880","journal-title":"Hematol Oncol"},{"key":"1376_CR19","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1182\/blood-2021-146491","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu W, Song Y, Wang T, Yang S, Liu L, Hu Y, Zhang W, Zhou J, Gao S, Ding K, Zhang H, Zhu Z, Wang S, Xu B, Hu J, Liu T, Ji C, Xia Z, Li Y, Wang X, Zhang B, Zhao R, Li J (2021) Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: updated long term results of phase II study. Blood 138:2638. https:\/\/doi.org\/10.1182\/blood-2021-146491","journal-title":"Blood"},{"key":"1376_CR20","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.ccr-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Elstrom R, Huang J, Novotny W, Wei R, Zhu J (2020) Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res 26:4216\u20134224. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-3703","journal-title":"Clin Cancer Res"},{"key":"1376_CR21","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Huang J, Novotny W, Kim P, Yu Y, Wu B, Zhu J (2022) Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139:3148\u20133158. https:\/\/doi.org\/10.1182\/blood.2021014162","journal-title":"Blood"},{"key":"1376_CR22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2019-126305","volume":"134","author":"Y Song","year":"2019","unstructured":"Song Y, Song Y, Liu L, Zhang M, Li Z, Ji C, Xu W, Liu T, Xu B, Wang X, Gao S, Zhang H, Hu Y, Li Y, Cheng Y, Yang H, Cao J, Zhu Z, Hu J, Zhang W, Jing H, Ding K, Lu Z, Zhang B, Zhao R, Xu Z, Zhu J (2019) Safety and Efficacy of Orelabrutinib Monotherapy in chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study. Blood 134:755\u2013755. https:\/\/doi.org\/10.1182\/blood-2019-126305","journal-title":"Blood"},{"key":"1376_CR23","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic L","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic L (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456. https:\/\/doi.org\/10.1182\/blood-2007-06-093906","journal-title":"Blood"},{"key":"1376_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer\/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin\u2019s Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study G, Southwest Oncology G, United Kingdom National Cancer Research I","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer\/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin\u2019s Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study G, Southwest Oncology G, United Kingdom National Cancer Research I (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"1376_CR25","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N (2016) NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE"},{"key":"1376_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ (2021) IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21:111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"key":"1376_CR27","unstructured":"Owen C, Peters A, Puckrin R, Shafey M, Tilley D, Cancer Care Alberta, Alberta Health Services (2022) Clinical practice guideline on chronic lymphocytic leukemia, version 8"},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA (2019) Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94:1353\u20131363. https:\/\/doi.org\/10.1002\/ajh.25638","journal-title":"Am J Hematol"},{"key":"1376_CR29","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/jco.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W (2020) ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 38:2849\u20132861. https:\/\/doi.org\/10.1200\/jco.19.03355","journal-title":"J Clin Oncol"},{"key":"1376_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/s1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, \u0160imkovi\u010d M, Shadman M, \u00d6sterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trn\u011bn\u00fd M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P (2022) Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 23:1031\u20131043. https:\/\/doi.org\/10.1016\/s1470-2045(22)00293-5","journal-title":"Lancet Oncol"},{"key":"1376_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M (2019) Ibrutinib-Rituximab or Chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381:432\u2013443. https:\/\/doi.org\/10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"key":"1376_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000850400.19760.77","author":"A Chanan-Khan","year":"2022","unstructured":"Chanan-Khan A, Liu T, Yang K, Cohen A, Fahrbach K, Campbell J, Tang B (2022) PB1887: Network meta-analysis of progression free survival in the treatment of relapsed of refractory chronic lymphocytic leukemia. HemaSphere. https:\/\/doi.org\/10.1097\/01.HS9.0000850400.19760.77","journal-title":"HemaSphere"},{"key":"1376_CR33","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14122.1","author":"M Schieber","year":"2018","unstructured":"Schieber M, Gordon LI, Karmali R (2018) Current overview and treatment of mantle cell lymphoma. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.14122.1","journal-title":"F1000Res"},{"key":"1376_CR34","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hern\u00e1ndez-Rivas J, Qi K, Deshpande S, Parisi L, Wang M (2019) Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 104:e211\u2013e214. https:\/\/doi.org\/10.3324\/haematol.2018.205229","journal-title":"Haematologica"},{"key":"1376_CR35","doi-asserted-by":"crossref","unstructured":"Song Y, Zhou K, Zou D (2021) Zanubrutinib (zanu)\u00a0in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a phase 2 study. In: European Hematology Association 2021 Virtual Congress","DOI":"10.1182\/blood.2021014162"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01376-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:03:16Z","timestamp":1692792196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01376-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}